Investment
Features
FeesSafety
Academy
More
Pluang+

Compare ADMA Biologics Inc (ADMA) vs Walt Disney Co (DIS) Price & Performance

ADMA Biologics IncTrade
Walt Disney CoTrade

Price performance (Past 24H)

Key statistics

ADMA Biologics Inc vs Walt Disney Co — how do they compare? ADMA Biologics Inc trades at $9.81 (market cap $2.18B), while Walt Disney Co trades at $103.53 (market cap $178.16B). The key difference: Walt Disney Co is far larger — about 81.7× ADMA Biologics Inc's market cap, and Walt Disney Co pays a 1.45% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.

ADMADIS
Market Cap
$2.18B$178.16B
Sector
HealthMedia
52-Week High
$20.38$118.86
52-Week Low
$7.60$92.40
Enterprise Value
$2.25B$219.02B
Volume
7,546,013
Dividend Yield
1.45%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

ADMA Biologics Inc

ADMA trades at $9.90, down 1.59% today, with strong profitability metrics including 64.71% gross margin and 41.9% ROE. Technical indicators show a bullish trend with support at $9-10, though RSI levels suggest overbought conditions. Recent earnings show mixed results with Q4 2025 beating expectations but Q1 and Q2 2026 missing estimates. The stock faces significant legal headwinds with multiple securities fraud lawsuits filed against the company.

Despite strong fundamentals and bullish analyst consensus (88.9% buy ratings), ADMA faces substantial legal risks from ongoing securities litigation that could impact shareholder value. The company's solid profit margins and growth trajectory provide upside potential, but investors should carefully weigh litigation risks against fundamental strength.

Walt Disney Co

Disney (DIS) trades at $103.51, down 1.32% on the day, with strong technical momentum and bullish moving average signals. The company demonstrates robust fundamentals with four consecutive quarterly earnings beats, revenue growth to $94.43B in 2025, and improving profit margins. Recent news highlights advertising opportunities from major events and ongoing FCC regulatory challenges.

Outlook remains positive with analyst consensus target of $126 representing 22% upside potential. Key opportunities include streaming growth and theme park investments, while risks involve regulatory disputes and box office performance variability. Wall Street maintains strong buy sentiment with 62.5% of analysts recommending purchase.

Returns comparison

Trailing returns across standard periods

About ADMA Biologics Inc

ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.

Read more on ADMA

About Walt Disney Co

The Walt Disney Company is an entertainment company with operations in media networks, park experiences & consumer products, studio entertainment and Direct-to-Consumer networks and channels. The Company serves customers worldwide.

Read more on DIS